Skip to main content

Advertisement

Table 2 Univariate and multivariate analyses in patients treated with chemotherapy

From: MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy

Variables EFS OS
HR (95% CI) P-value HR (95% CI) P-value
Univariate analyses
 MiR-425 (high vs. low) 0.449 (0.279–0.721) 0.001 0.506 (0.316–0.811) 0.005
 WBC (≥ 20 vs. < 20 × 109/L) 0.939 (0.594–1.484) 0.786 0.936 (0.591–1.484) 0.779
 FLT3-ITD (positive vs. negative) 1.242 (0.693–2.224) 0.467 1.192 (0.665–2.136) 0.555
 NPM1 (mutated vs. wild) 1.168 (0.721–1.893) 0.527 1.044 (0.640–1.704) 0.862
 DNMT3A (mutated vs. wild) 1.491 (0.909–2.446) 0.114 1.432 (0.868–2.362) 0.160
 RUNX1 (mutated vs. wild) 1.464 (0.700–3.064) 0.312 1.591 (0.759–3.335) 0.219
 TP53 (mutated vs. wild) 2.949 (1.510–7.561) 0.002 2.898 (1.487–5.694) 0.002
 CEBPA (mutated vs. wild) 2.963 (0.910–9.648) 0.071 2.901 (0.892–9.434) 0.077
 IDHI/IDH2 (mutated vs. wild) 1.006 (0.570–1.775) 0.983 0.954 (0.532–1.710) 0.874
 NRAS/KRAS (mutated vs. wild) 1.143 (0.601–2.172) 0.684 1.188 (0.625–2.260) 0.599
 MLL-PTD (mutated vs. wild) 0.836 (0.305–2.291) 0.727 0.910 (0.332–2.495) 0.855
Multivariate analyses
 MiR-425 (high vs. low) 0.432 (0.266–0.703) 0.001 0.502 (0.311–0.811) 0.005
 FLT3-ITD (positive vs. negative) 1.582 (0.868–2.883) 0.134 – –
 TP53 (mutated vs. wild) 2.737 (1.377–5.438) 0.004 2.519 (1.286–4.933) 0.007
 CEBPA (mutated vs. wild) 3.746 (1.102–12.736) 0.034 3.228 (0.959–10.864) 0.058
  1. EFS event-free survival, OS overall survival, HR hazard ratio, CI confidence interval, WBC white blood cell, FLT3-ITD internal tandem duplication of the FLT3 gene, NPM1 nucleophosmin, DNMT3A DNA methyltransferase 3A, RUNX1 runt related transcription factor 1, MLL-PTD partial tandem duplication of the MLL gene, CEBPA CCAAT/enhancerbinding protein α, IDH isocitrate dehydrogenase
  2. Cox proportional hazards model was used for EFS and OS. HRs greater than 1.0 indicate higher and those less than 1.0 indicate lower risk for EFS or OS
Back to article page